1. Home
  2. ESLT vs GMAB Comparison

ESLT vs GMAB Comparison

Compare ESLT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elbit Systems Ltd.

ESLT

Elbit Systems Ltd.

SELL

Current Price

$722.69

Market Cap

33.8B

Sector

Industrials

ML Signal

SELL

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

SELL

Current Price

$51.86

Market Cap

31.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ESLT
GMAB
Founded
1966
1999
Country
Israel
Denmark
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.8B
31.9B
IPO Year
2002
2008

Fundamental Metrics

Financial Performance
Metric
ESLT
GMAB
Price
$722.69
$51.86
Analyst Decision
Hold
Strong Buy
Analyst Count
6
12
Target Price
★ $841.50
$65.01
AVG Volume (30 Days)
69.3K
★ 6.0M
Earning Date
11-17-2026
11-05-2026
Dividend Yield
★ 0.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.64
$27.61
Revenue Next Year
$14.29
$21.18
P/E Ratio
$71.88
★ $1.90
Revenue Growth
N/A
N/A
52 Week Low
$453.00
$23.62
52 Week High
$1,016.06
$59.97

Technical Indicators

Market Signals
Indicator
ESLT
GMAB
Relative Strength Index (RSI) 49.10 59.95
Support Level $650.34 $24.87
Resistance Level $743.83 $59.97
Average True Range (ATR) 24.43 2.00
MACD -4.20 -0.80
Stochastic Oscillator 41.59 13.24

Price Performance

Historical Comparison
ESLT
GMAB

About ESLT Elbit Systems Ltd.

Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security and commercial flight capabilities. Its systems and solutions may be installed on new platforms or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company operates in five segments: Aerospace; C4I and Cyber; ISTAR and EW; Land; and ESA. It derives maximum revenue from Land Segment. Geographically, it operates in Israel; North America; Europe; Asia-Pacific; Latin America; and Others.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: